On March 8, 2022 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported that preclinical, translational, and clinical biomarker data from its oncology pipeline have been selected for four poster presentations at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (AACR) (Free AACR Whitepaper), taking place April 8-13 (Press release, Hookipa Pharma, MAR 8, 2022, View Source [SID1234609675]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We’re thrilled to have four poster presentations accepted at AACR (Free AACR Whitepaper) as they provide further evidence of the broad potential of our arenaviral platform to address unmet needs in various types of cancer, either alone or in combination with other modalities," said Joern Aldag, Chief Executive Officer at HOOKIPA. "New translational data from our ongoing Phase 1/2 trial in head and neck cancers continue to show strong T cell responses, and new preclinical data further support our early-stage prostate cancer program, as well as highlight new potential combination approaches."
The AACR (Free AACR Whitepaper) posters provide a broad preclinical, translational, and clinical biomarker dataset highlighting the versatility and therapeutic utility of replicating arenavirus vectors to activate and augment tumor-specific CD8+ T cell responses for tumor killing. Specifically, the data support the potential of arenaviral vectors to target self and non-self tumor antigens and be used as monotherapy or in combination with other modalities. The abstracts are available on the AACR (Free AACR Whitepaper) website.
Abstract # 2038: In vitro and in vivo characterization of non-oncolytic engineered arenavirus for cancer immunotherapy
This detailed preclinical and translational characterization of arenavirus vectors based on Lymphocytic choriomeningitis virus and Pichinde virus shows anti-tumor effects in preclinical models, as well as infection and activation of human professional antigen-presenting cells key for eliciting a robust tumor specific CD8+ T cell response.
In person poster presentation
Monday, April 11, 1:30pm – 5:00pm CT
Presenter: Henning Lauterbach, HOOKIPA
Abstract # 3284: HB-201 and HB-202, an arenavirus-based immunotherapy, induces tumor T cell infiltration in patients with HNSCC and other HPV16+ tumors
These data demonstrate that HB-201 and HB-202/HB-201 rapidly induce unprecedented levels of systemic, tumor-specific CD8+ T cells in patients with Human Papilloma Virus 16-positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) after one dose. In addition, the data show a sustained polyfunctional profile of these cells during treatment, infiltration of CD8+ T cells into tumors and decrease of HPV16+ DNA in tumor tissue, in line with the proposed mode of action of the therapy.
In person poster presentation
Tuesday, April 12, 1:30pm – 5:00pm CT
Presenter: Henning Lauterbach, HOOKIPA
Abstract # 3298: Propagation competence of a self-antigen-targeting arenavirus vector-based cancer therapy determines antitumor efficacy in mouse melanoma
These data highlight the crucial role of replication competence of arenavirus-based vectors for: overcoming immune tolerance; robust induction of CD8+ T cell responses against tumor self-antigens; and activation and amplification of adoptively transferred TCR transgenic CD8+ T cells in a combination therapy which proved able to induce complete tumor remission in mice.
In person poster presentation
Tuesday, April 12, 1:30pm – 5:00pm CT
Presenter: Klaus Orlinger, HOOKIPA
Abstract # 4198: Evaluation of a cancer immunotherapy with engineered arenavirus vectors and 4-1BB agonists in a preclinical tumor model
The data demonstrate one strategy to unlock the potential of arenavirus vector-induced CD8+ T cell responses for tumor killing in a combination therapy with 4-1BB agonists.
In person poster presentation
Wednesday, April 13, 9:00am – 12:30pm CT
Presenter: Judith Strauss, HOOKIPA
About HB-202/HB-201
HB-201 and HB-202 are HOOKIPA’s lead oncology candidates engineered with the company’s proprietary replicating arenaviral vector platform. Each single-vector compound uses a different arenavirus backbone (Lymphocytic Choriomeningitis Virus for HB-201 and Pichinde Virus for HB-202), while expressing the same antigen, an E7E6 fusion protein derived from HPV16. In pre-clinical studies, alternating administration of HB-201 and HB-202 resulted in a ten-fold increase in immune response and better disease control than either compound alone.
About the HB-200 trial (NCT04180215)
This Phase 1/2 clinical trial is an open-label trial exploring different dose levels and dosing schedules in individuals with treatment-refractory HPV16+ head and neck cancers who progressed on standard of care, including check point inhibitors. The trial is evaluating HB-201 as a monotherapy, as an alternating 2-vector therapy with HB-202, and in combination with a PD-1 inhibitor. The primary endpoint of Phase 1 is a recommended Phase 2 dose. Secondary endpoints include safety and tolerability, as well as preliminary efficacy defined by RECIST 1.1. The study also includes exploratory objectives on immunogenicity and pharmacodynamic biomarkers.